The Chiesei Group, an Italian conglomerate, said Monday it has agreed to acquire Zymenex Holding A/S and its related group of companies (“Zymenex”), a biopharmaceutical group focused on research and development of biologic therapeutics for the treatment of rare and life threatening genetic diseases.

As quoted in the news release:

“We are excited to announce this transaction, which marks Chiesi’s entrance into the rare disease space and provides an opportunity to access high-potential markets,” said Ugo Di Francesco, CEO of Chiesi. “By expanding our research and development assets and know-how, we believe we can successfully commercialize new and developing drugs to enhance our portfolio, expand our international footprint and strengthen our competitive position.”

Read the full press release by Zymenex Holding A/S and Chiesi Farmaceutical S.p.A.

rare disease Company News